Background: A portion of children with Langerhans cell histiocytosis (LCH) exhibit recurrent or persistent disease-related fever at their first visit. We aimed to clarify the clinical characteristics, laboratory indicators, prognostic differences, and optimal regimens for these children with fever. Methods: A cross-sectional design (single-center, retrospective, and observational) was adopted for this study. A total of 448 pediatric patients diagnosed with LCH in our hospital from January 2016 to December 2019 were retrospectively enrolled and divided into two groups: children with fever (n=52) and children without fever (n=396). The clinical characteristics, laboratory indicators, and outcomes of regimens for these children were analyzed with SPSS 16.0 software. Results: Children with initial fever had distinct clinical characteristics and laboratory indicators, including an age younger than two years, risk-organ involvement, accompanying hemophagocytic syndrome, and higher levels of cell-free DNA BRAFV600E mutation, among others. Patients in the fever group also had a significantly lower treatment efficacy from first-line treatment and a lower 3-year progression-free survival (PFS) rate (approximately 5.22% and 64.23%, respectively; P<0.001). Multivariate Cox regression analysis indicated that fever, risk-organ involvement, skin involvement, ferritin level, and dynamic erythrocyte sedimentation rate were independently prognostic factors for outcomes of first-line treatment. However, the 3-year PFS rates did not differ significantly between patients with fever and without fever after the administration of second-line or target regimens. Conclusions: Among pediatric patients with LCH, those with initial fever exhibit more severe clinical symptoms and worse prognoses after first-line chemotherapy. Alternative strategies may mitigate fever-associated risk, and this possibility should be confirmed through prospective research.